As the earning season continues, more companies are likely to announce profits before the market opens on July 29, 2022. Here are some of the expected earnings announcements;
Exxon Mobil Corporation
Exxon Mobil Corporation (XOM) is releasing quarterly results for the period ending 30 June 2022. The consensus earnings per share estimate from the nine analysts that track the stock is $3.80.
This indicates an increase of 245,45 per cent compared to the previous quarter. XOM missed the consensus EPS estimate for the first quarter of 2022 by eight per cent.
According to Investment analysts, the Price to Earnings ratio for XOM in 2022 is 7.64, while the ratio for the industry is 5.30, indicating that XOM will have a faster earnings growth than its competitors in the same industry.
Procter & Gamble Company (The)
Procter & Gamble Company (PG)is reporting for the quarter ending June 30, 2022. The cleaning company’s consensus earnings per share projection from the 9 analysts that cover the stock is $1.23. This amount reflects an 8.85 per cent rise compared to the same quarter previous year.
In the previous year, PG outperformed the forecasts every quarter. The highest one came in the 1st calendar quarter, surpassing the estimate by 3.91 per cent.
Analysts say that the 2022 Price to Earnings ratio for PG is 24.98 vs. an industry ratio of 24.50, meaning that they will have a stronger earnings growth than their competitors in the same industry.
Chevron Corporation (CVX) is reporting quarterly results for the period ending 30 June 2022.
The consensus estimate for the oil company’s earnings per share from the 9 analysts who track the stock is $5.02. This represents an increase of 193.57 per cent compared to last year’s quarter.
The last two quarters have shown negative earnings surprises for CVX, with the most recent report missing by -2.33 per cent.
According to market research, CVX’s 2022 Price to Earnings ratio is 8.26, while the industry ratio is 5.30, indicating that CVX will have higher earnings growth than its competitors in the same industry.
AbbVie Inc. (ABBV) announces its quarterly results for the period ending June 30, 2022. The consensus estimate of earnings per share for the large-cap pharmaceutical business from the three analysts that track the stock is $3.42.
This marks an increase of 9.97 per cent compared to the same quarter the previous year. During the past year, ABBV has matched analyst expectations once and exceeded them three times.
According to investment researchers, the Price to Earnings ratio for ABBV in 2022 is 10.77, compared to the industry average of 15.90.
Linde plc (LIN) has lifted its full-year 2022 adjusted EPS guidance to $11.73-11.93, which implies a gain of 10 per cent to 12 per cent year-over-year.
For the third quarter, the business forecasts adjusted earnings per share in a range of $2.85-$2.95, which implies an increase of 4 per cent to 8 percent year-over-year.
The adjusted earnings per share from continuing operations for the second quarter was $3.10, compared to $2.70 last year. Profit from continuing operations was $372 million or $0.74 per share compared to $840 million or $1.60 per share last year. Sales grew to $8.46 billion from $7.58 billion a year before.
Shares of Linde plc are down 2 per cent in pre-market activity on Thursday.
CAT is projected to show an improvement in both top- and bottom lines when it releases second-quarter 2022 earnings on Aug 2, before the opening bell. Strong demand in its end markets and price moves that are believed to have countered the impact of elevated costs and supply chain interruptions are likely to have propelled the to-be-reported quarter’s results.
The Consensus Estimate for quarterly profits per share for the quarter is presently pegged at $2.99, which shows an increase of 15 per cent from the year-ago reported amount.
The consensus estimate for overall sales sits at $14.3 billion, reflecting an increase of 11 per cent from the prior-year quarter.
All information has been prepared by TraderFactor or partners. The information does not contain a record of TraderFactor or partner’s prices or an offer of or solicitation for a transaction in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. Any material provided does not have regard to the specific investment objective and financial situation of any person who may read it. Past performance is not a reliable indicator of future performance.